Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
Journal Title: Journal of Vaccines & Immunization - Year 2015, Vol 3, Issue 2
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardiovascular disease, pulmonary disease, or diabetes mellitus). This analysis is consistent with data suggesting immunocompetent at-risk populations aged ≥50 years produce functional anti-pneumococcal antibody responses to PCV13 comparable to those not at risk. An OPA titer that correlates with protection has not been defined for adults; however, PCV13 elicits generally higher responses than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) one month after vaccination. PCV13 vaccination of immunocompetent at-risk populations likely results in benefits analogous to those without additional risk.
Authors and Affiliations
Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Sundaraiyer V, Gruber WC, Scott DA, Isturiz RE
Keywords
Related Articles
- EP ID EP566654
- DOI 10.14312/2053-1273.2015-2
- Views 51
- Downloads 0
Suboptimal vaccination rates in rural Ghana despite positive caregiver attitudes towards vaccination
Background: Vaccines save more than 3 million lives and prevent 750,000 disabilities each year. Optimum immunization coverage will help in the fight against infectious diseases. This study was carried out to characterize...
Comparison of the live attenuated mumps vaccine (Miyahara strain) with its preattenuated parental strain
Live attenuated mumps vaccines have been developed by passaging the field isolates in cells that differ from the natural host. To study mumps viral (MuV) attenuation at the genomic level, we compared a live attenuated mu...
Events following BCG vaccination during neonatal period and factors that might affect potency and side effects
Introduction: In Sri Lanka, BCG vaccine is given during neonatal period. There are many myths regarding BCG vaccine and sequelae of vaccination are not clearly documented in medical literature. Objectives: Objectives of...
Hospital epidemiology and costs of pertussis in France: A retrospective database analysis
Background: Pertussis vaccination coverage remains unsatisfactory in adults in France and pertussis is the leading cause of death due to bacterial infection in infants up to 3 months of age, whom are most often infected...
Impact of strategies and activities for reducing morbidity and mortality of vaccine-preventable diseases in Oman: A status report
Immunization is the only child survival strategy which alone averts two to three million deaths each year. This has been possible because of high coverages achieved by many countries in the world. Still nearly 1.5 millio...